Publication: Early i-IFTA: Associated factors and impact on graft outcome
Authors
Tristan De Nattes ; Damien Sizaret ; Philippe Gatault ; Christine Bonenfant ; Claire Kizlik ; Lucie Maigret ; Marie-Christine Machet ; Marion Rabant ; Juliette Gueguen ; Elodie Miquelestorena-Standley ; Antoine Taillandier
item.page.secondaryauthor
item.page.director
Publisher
publication.page.editor
Universidad de Murcia, Departamento de BiologÃa Celular e HistologÃa
publication.page.department
DOI
https://doi.org/10.14670/HH-25-005
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Assessment of inflammation in scarred
cortical parenchyma of kidney transplant (i-IFTA) is a
criterion for chronic active T cell-mediated rejection
(TCMR) and has mainly been explored in one-year
protocol biopsies. We evaluated the factors, molecular
profile, and one-year graft outcome associated with early
i-IFTA. We included 101 kidney transplant biopsies
performed within the first six months posttransplant
(median=89 days), between 2009 and 2020. Interstitial
inflammation Banff criteria were retrospectively re
evaluated, and diagnosis reclassification was performed
according to the Banff 2022 classification. After re
evaluation, 85% of the biopsies presented no rejection,
including 16% of biopsies from patients with delayed
graft function, and 5% of biopsies with BK polyoma
virus nephropathy. Eleven per cent (11%) of the biopsies
presented histological TCMR. Delayed graft function
was associated with i-IFTA severity (OR=2.78, 95%
CI:1.01-7.68, p=0.049). The molecular profile obtained
in 93 biopsies revealed that 86% presented a no-rejection
profile and that a TCMR molecular profile tended to be
more frequent in biopsies with i-IFTA2/3 compared with
i-IFTA0/1 (17% vs. 4%, p=0.060). I-IFTA0/1 and 2/3
presented comparable one-year graft outcomes,
including donor-specific antibodies (DSA), rejection
occurrence, and graft function. In conclusion, early i
IFTA is an ambiguous and non-specific lesion that can
be associated with ischemia/reperfusion injury, early BK nephropathy, or rejection.
publication.page.subject
IFTA , i-IFTA , T-Cell mediated rejection , TCMR , AMR , CA TCMR , Chronic active TCMR , Kidney graft
Citation
item.page.embargo
Ir a EstadÃsticas
Este Ãtem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/